Zdeněk Adam

Research interests

Publications

• Deregulated expression of long non‐coding RNA UCA 1 in multiple myeloma

  European Journal Of Haematology · 2017 · 10.1111/ejh.12908

• Various forms of 18F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica

  Biomedical Papers · 2015 · 10.5507/bp.2015.026

• Cytogenetics in multiple myeloma patients progressing into extramedullary disease

  European Journal Of Haematology · 2015 · 10.1111/ejh.12688

• Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

  Haematologica · 2014 · 10.3324/haematol.2014.115204

• Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

  Haematologica · 2013 · 10.3324/haematol.2013.093500

• Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results

  Neoplasma · 2012 · 10.4149/neo_2012_057

• Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment

  Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 10.3109/10428194.2012.738816

• Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases

  Acta Oncologica · 2012 · 10.3109/0284186x.2012.716164

• Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen

  Clinical Lymphoma Myeloma & Leukemia · 2011 · 10.1016/j.clml.2011.06.014

• Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

  Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 10.3109/10428194.2011.634042

• A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

  Blood · 2011 · 10.1182/blood.v118.21.475.475

• Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma

  Neoplasma · 2010 · 10.4149/neo_2010_01_029

• Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

  Haematologica · 2010 · 10.3324/haematol.2009.020586

• Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2010.28.1238

• Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response

  Annals of Hematology · 2009 · 10.1007/s00277-009-0834-3

• Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib

  Clinical Lymphoma & Myeloma · 2009 · 10.3816/clm.2009.n.036

• Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.

  Blood · 2007 · 10.1182/blood.v110.11.3603.3603

• Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance.

  PubMed · 2007

• Langerhans cell histiocytosis with central nervous system involvement: Follow‐up by FDG‐PET during treatment with cladribine

  Pediatric Blood & Cancer · 2004 · 10.1002/pbc.20175

Current projects

No projects listed.